Abstract
Recombinant human 5-HT1Dα and 5-HT1Dβ receptor subtypes were stably expressed in NIH-3T3 fibroblasts (1Dα cell line) and Y-1 adrenocortical tumor cells (1Dβ cell line), respectively, for pharmacological evaluations of serotonergic compounds to inhibit forskolin-stimulated CAMP accumulation (FSCA). [3H]LSD saturation studies indicated that 5-HT1D receptor expression levels were slightly higher in the 1Dβ cell line (B max = 1334 ± 134 fmol/mg protein) than in the (1Dα) cell line (B max = 900 ± 900 fmol/mg protein). 5-HT inhibited FSCA with similar potencies (EC50 ≈ 2 nM) in both assay systems. The rank order of agonist potencies in both clonal cell lines matched their pharmacological profiles previously determined in binding studies: dihydroergotamine >- 5-carboxamidotryptamine (5-CT) > LSD >- 5-HT > sumatriptan > 1-naphthylpiperazine (1-NP) > yohimbine > 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT) > 1-(2,5-dimethoxy4-iodophenyl)-2-aminopropane (DOI), with Ki/EC50 ratios greater than unity. Methiothepin acted as a silent antagonist at both human 5-HT1Dα and 5-HT1Dβ receptors with apparent dissociation constants (Kb values) of 12 ± 1 nM and 3 ± 1 nM, respectively. Whereas GR 127,935, metergoline, DOI, and quipazine acted as full agonists in the 1Dα cell line, these compounds behaved as partial agonists in the 1Dβ cell line.
To determine whether high levels of receptor reserve might mask partial agonist activity in the two second messenger assay systems, studies were performed using the irreversible receptor alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). The relationships between receptor occupancy and inhibition of FSCA were determined for 5-HT, sumatriptan, and 1-NP in both clonal cell lines after partial receptor inactivation using Furchgott analysis. Hyperbolic relationships between receptor occupancy and second messenger response were determined for 5-HT in both transfected cell lines. Steep hyperbolic relationships were also found for sumatriptan and 1-NP in the 1Dβ cell line whereas nearly linear relationships were observed for these two compounds in the 1Dα cell line. Moreover, KA/EC50 ratios of these compounds were significantly larger in the (1Dα)(10–32) as compared to the 1Dα (0.9–2.5) cell line. These data are consistent with the hypothesis that the two heterologous expression systems contain a differential amount of receptor reserve. Despite the presence of an apparently larger receptor reserve in the 1Dβ cell line, GR 127,935, metergoline, DOI, and quipazine behaved as partial agonists.
Although the potencies (EC50 values) of compounds matched their respective affinity constants (Ki values) for the closely-related 5-HT1D subtypes, differences in intrinsic activities were observed for a few compounds between the two 5-HT1D receptor expression systems. Since receptor reserve is dependent on the properties of both the assay system and drug, the observed variations in intrinsic activity, although influenced by the variable amounts of receptor reserve in the two transfected cell lines, reflect primarily system-independent differences in the intrinsic efficacy of the tested compounds at the two human 5-HT1D receptors. Higher intrinsic efficacies of compounds at the human 5-HT1Dα receptor relative to the human 5-HT1Dβ subtype may be responsible for the higher intrinsic activities observed in the (1Dα) cell line, even though receptor reserve is apparently lower in this system.
Similar content being viewed by others
Abbreviations
- CRC :
-
Concentration-response curve
- FSCA :
-
forskolin-stimulated cAMP accumulation
- KA:
-
pseudo-dissociation constants
- 5-CT :
-
5-carboxamidotryptamine
- 5-HT :
-
5-hydroxytryptamine
- 5MeOT :
-
5-methoxytryptamine
- PAPP:
-
1-[2-(4-aminophenyl) ethyl] -4-(3-trifluoromethylphenyl)-piperazine
- 1-NP :
-
1-(1-naphthyl) piperazine
- 8-OH-DPAT :
-
8-hydroxy-2-(di-n-propylamino) tetralin
- DOI :
-
1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
- MK-462:
-
(N,N-dimethyl-2-[5-(1, 2, 4-triazol-l-yl methyl)-1H-indole3-yl]ethylamine
- GR :
-
127,935 (2′-methyl-4′-(5-methyl-[1, 2, 4]oxadiazol-3-yl)-biphenyl-4-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide)
- GR :
-
46611 5-[4-methoxybenzyl ethylene]-1H-indole3-yl]ethyl amine)
- L-694,247 :
-
(2-[5-[3-(4-methylsulfonylamino)benzyl-1, 2, 4-oxadiazol-5-yl]-1H-indole3-yl]ethylamine)
References
Aburto TK, Lajoie C, Morgan KG (1993) Mechanisms of signal transduction during α2-adrenergic receptor-mediated contraction of vascular smooth muscle. Circ Res 72:778–785
Adham N, Romanienko P, Hartig P, Weinshank RL, Branchek T (1992) The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptaminelDβ receptor. Mol Pharmacol 41:1–7
Adham N, Ellerbrock B, Hartig P, Weinshank RL, Branchek T (1993a) Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mot Pharmacol 43:427–433
Adham N, Borden LA, Schechter LE, Gustafson EL, Cochran TL, Vaysse PJ-J, Weinshank RL, Branchek TA (1993b) Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways. Naunyn-Schmiedeberg's Arch Pharmacol 348:566–575
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48–58
Bax WA, Renzenbrink GJ, Heuven-Nolsen DV, Thijssen EJM, Bos E, Saxena PR (1993) 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 239: 203–210
Beer MS, Middlemiss DN (1993) Serotonin-5-O-carboxymethylglycyl[125I]tyro sinamide labels the 5-HT1Dβ receptor subtype in human cortex. Eur J Pharmacol 242:195–198
Beer MS, Stanton JA, Bevan SY, Heald A, Reeve AJ, Street LJ, Matassa VG, Hargreaves RJ, Middlemiss DN (1993) L-694,247: a potent 5-HT1D receptor agonist. Br J Pharmacol 110: 1196–1200
Beer MS, Middlemiss DN, Stanton JA, Longmore J, Hargreaves R, Noble A, Scholey K, Bevan Y, Hill R, Baker R, Street L, Matassa V, Iverson L (1994) An in vitro pharmacological profile of the novel anti-migraine 5-HT1D receptor agonist MK-462 (abstract). Third IUPHAR Satellite Meeting on Serotonin, p.105
Boddeke HWGM, Fargin A, Raymond JR, Schoeffter P, Hoyer D (1992) Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells. Naunyn-Schmiedeberg's Arch Pharmacol 345:257–263
Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Branchek TA, Adham N, Macchi MJ, Kao HT, Hartig PR (1990)[3H]DOB (4-bromo-2,5-dimethoxy-phenylpropylamine) and [3H]ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mot Pharmacol 38:604–609
Branchek T, Adham N, Zgombick J, Schechter L, Hartig P, Gustafson E, Weinshank R (1992) Differential host preference in functional coupling of cloned 5-HT 1D subtypes in heterologous expression systems (abstract). Second International Symposium on Serotonin: From Cell Biology to Pharmacology and Therapeutics, p 10
Bruinvels AT, Palacios JM, Hoyer D (1993) Autoradiographic characterization and localization of 5-HT1Dα compared to 5-HTIB binding sites in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 347:569–582
Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, Hoyer D, Palacios JM (1994) Localization of 5-HT1B, 5-HT1Dα, 5-HT1E, and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropbarmacology 33:367–382
Chopin P, Moret C, Briley M (1994) Neuropharmacology of 5-hydroxytryptamineB/D receptor ligands. Pharmacol Ther 62: 385–405
Conklin BR, Bourne HR (1993) Structural elements of Gα subunits that interact with Gβγ, receptors, and effectors. Cell 73:631–641
Demchyshyn L, Sunahara RK, Miller K, Teitler M, Hoffman BJ, Kennedy JL, Seeman P, Van Tol HHM, Niznik HB (1992) A human serotonin 1D receptor variant (5-HT1Dβ) encoded by an intronless gene on chromosome 6. Proc Natl Acad Sci USA 89:5522–5526
Ebersole BJ, Diglio CA, Kaufman DW, Berg KA (1993) 5-Hydroxytryptamine1-like receptors linked to increases in intracellular calcium concentration and inhibition of cyclic AMP accumulation in cultured vascular smooth muscle cells derived from bovine basilar artery. J Pharmacol Exp Ther 266:692–699
Furchgott RF, Bursztyn P (1967) Comparison of dissociation constants and relative efficacies of selected agonists acting on parasympathetic receptors. Ann NY Acad Sci 144:882–899
Gazlin AM, Poirer MF, Lista A, Chodkiewicz JP, Blier P, Ramdine R, Loo H, Roux FX, Redondo A, Langer SZ (1992) Characterization of the 5-hydroxytryptamine receptor modulating the release of 5-[3H]hydroxytryptamine in slices of the human neocortex. J Neurochem 59:1293–1301
Göthert M, Fink K, Frölich D, Likungu J, Molderings G, Schlicker E, Zentner J (1996) Presynaptic 5-HT auto- and heteroreceptors in the human central and peripheral nervous system. Behav Brain Res 73:89–92
Hamblin MW, Metcalf MA (1991) Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol 40:143–148
Hamel E, Bouchard D (1991) Contractile 5-HT1 receptors in human isolated pial arterioles: correlation with 5-HT1D binding sites. Br J Pharmacol 102:227–233
Hamel E, Fan E, Linville D, Ting V, Villemure J-G, Chia L-S (1993) Expression of mRNA for the serotonin 5-hydroxytryptamine1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 44:242–246
Hartig PR, Branchek TA, Weinshank RL (1992) A subfamily of 5-HT1D receptor genes. Trends Pharmacol Sci 13:152–159
Hoyer D, Schoeffter P, Waeber C, Palacios JM (1990) Serotonin 5-HT1D receptors. Ann NY Acad Sci 600:168–181
Hoyer D, Boddeke HWGM (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14:270–275
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157–203
Jin H, Oksenberg D, Ashkenazi A, Peroutka S, Duncan AMV, Rozmahel R, Yang Y, Mengod G, Palacios JM, O'Dowd BF (1992) Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem 267:5735–5738
Kaumann AJ, Parsons AA, Brown AM (1993) Human arterial constrictor serotonin receptors. Cardiovasc Res 27:2094–2103
Kenakin T (1993a) Pharmacological analysis of drug-receptor interaction. Raven Press, New York, pp 46–49
Kenakin T (1993b) Pharmacological analysis of drug-receptor interaction. Raven Press,New York, pp 255–258
Kucharewicz S, Zgombick JM, Adham N, Weinshank RL, Branchek TA (1994) Binding profile assessment of hallucinogenic compounds at cloned human 5-HT1 receptors (abstract). Third IUPHAR Satellite Meeting on Serotonin, p.116
Levy FO, Gudermann T, Perez-Reyes E, Birnbaumer M, Kaumann AJ, Birnbaumer L (1992) Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT1D subtype. J Biol Chem 267:7553–7562
Manuel NA, Wallis DI, Crick H (1995) Ketanserin-sensitive depressant actions of 5-HT1 receptor agonists in the neonatal rat spinal cord. Br J Pharmacol 116:2647–2654
Maura G, Thellung S, Andrioli GC, Ruelle A, Raiteri M (1993) Release-regulating serotonin 5-HT1D autoreceptors in human cerebral cortex. J Neurochem 60:1179–1182
Miller KJ, King A, Demchyshyn L, Niznik H, Teitler M (1992) Agonist activity of sumatriptan and metergoline at the human 5-HT(1Dβ) receptor: further evidence for a role of the 5-HT1D receptor of the action of sumatriptan. Eur J Pharmacol Mol Pharmacol Sect 227:99–102
Parsons AA, Whalley ET, Feniuk W, Connor HE, Humphrey PPA (1989) 5-HT1-like receptors mediates 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol 96:434–449
Pauwels PJ, Colpaert FC (1995) Functional effects of the 5-HT1D receptor antagonist GR 127,935 at human 5-HT1Dα, 5-HT1Dβ, 5-HT1A and opossum 5-HT1B receptors. Eur J Pharmacol Mol Pharmacol Sect 290:95–103
Pauwels PJ, Palmier C, Wurch T, Colpaert FC (1996) Pharmacology of cloned human 5-HT1D receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT1D and 5-HT1B receptors. Naunyn-Schmiedeberg's Arch Pharmacol 353:144–156
Piñeyro G, de Montigny C, Blier C (1994) 5-HT1D receptors regulate 5-HT release in rat raphe nuclei: in vivo voltammetry and in vitro superfusion studies. Neuropsychopharmacology 13:249–260
Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP (1991) Structure and function of α-adrenoceptors. Pharmacol Rev 43:475–505
Skingle M, Scopes DIC, Feniuk W, Connor HE, Carter MC, Citherow JW, Tyers MB (1993) GR 127,935: a potent, orally active 5-HT1D receptor antagonist. Br J Pharmacol 110:9P
Southern PJ, Berg P (1982) Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of SV40 early region promoter. J Mol Appl Genet 1:327–354
Thomas DR, Faruq SA, Balcarek JM, Brown AM (1995) Pharmacological characterisation of [35S]GTPγS binding to Chinese Hamster Ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes. J Rec Sign Transduc Res 15:199–211
Varrault A, Journot L, Audigier Y, Bockaert J (1992) Transfection of human 5-hydroxytryptamine1A receptors in NIH-3T3 fibroblasts: effects of increasing receptor density on the coupling of 5-hydroxytryptamine1A receptors to adenylyl cyclase. Mol Pharmacol 41:999–1007
Veldman SA, Bienkowski MJ (1992) Cloning and pharmacological characterization of a novel 5-hydroxytryptamine1D receptor subtype. Mol Pharmacol 42:439–444
Waeber C, Schoeffter P, Hoyer D, Palacios JM (1990) The serotonin 5-HT1D receptor: a progress review. Neurochem Res 15:567–582
Walsh DM, Beattie DT, Connor HE (1995) The activity of 5-HT1D receptor ligands at cloned human 5-HT1Dα and 5-HT1Dβ receptors. Eur J Pharmacol 287:79–84
Watson J, Burton M, Price GW, Jones BJ, Thomas D, Faruq A, Middlemiss DN (1995) GR 127935 acts as a partial agonist at recombinant human 5-HT1Dα, and 5-HT1Dβ receptors. Br J Pharmacol 114:362P
Weinshank RL, Zgombick JM, Macchi M, Branchek TA, Hartig PR (1992) The human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. Proc Natl Acad Sci USA 89:3630–3634
Zgombick JM, Weinshank RL, Macchi M, Schechter LE, Branchek TA, Hartig PR (1991) Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype. Mol Pharmacol 40:1036–1042
Zgombick JM, Borden LA, Cochran TL, Kucharewicz SA, Weinshank RL, Branchek TB (1993) Dual coupling of cloned human 5-hydroxytryptamine1Dα and 5-hydroxytryptamine1Dβ receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concentrations via pertussis-toxin sensitive Gα protein(s). Mol Pharmacol 44:575–582
Zgombick JM, Schechter LE, Kucharewicz S, Weinshank RL, Branchek TA (1995) Ketanserin and ritanserin discriminate between recombinant human 5-HT1Dα and 5-HT1Dβ receptor subtypes. Eur J Pharmacol Mol Pharmacol Sect 291:9–15
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zgombick, J.M., Schechter, L.E., Adham, N. et al. Pharmacological characterizations of recombinant human 5-HT1D1Dα and 5-HT1Dβ receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 354, 226–236 (1996). https://doi.org/10.1007/BF00171052
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00171052